用于胰腺腺癌的生物标志物驱动和分子靶向治疗。
Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
机构信息
Division of Medical Oncology, Department of Medicine, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy.
出版信息
Semin Oncol. 2018 Jun;45(3):107-115. doi: 10.1053/j.seminoncol.2018.05.004. Epub 2018 Jun 5.
Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease with few effective treatment options. Our knowledge of molecular alterations in PDAC has significantly grown and helped identify new therapeutic targets. The success of immune checkpoint inhibition in mismatch repair deficient tumors, PARP inhibitors for tumors with DNA repair defects, and targeting hyaluronan with PEGPH20 in patients with high expressing (hyaluronan-high) tumors are examples of promising biomarker-driven therapies. We review the major biological mechanisms in PDAC and discuss current and future directions for molecularly targeted therapies in this disease.
胰腺导管腺癌（PDAC）仍然是一种致命的疾病，治疗选择有限。我们对 PDAC 分子改变的认识有了显著的提高，并帮助确定了新的治疗靶点。免疫检查点抑制剂在错配修复缺陷肿瘤中的成功、PARP 抑制剂在具有 DNA 修复缺陷的肿瘤中的应用，以及针对高表达（透明质酸高）肿瘤的透明质酸与 PEGPH20 结合的治疗方法，都是有前景的生物标志物驱动治疗的例子。我们回顾了 PDAC 的主要生物学机制，并讨论了这种疾病中分子靶向治疗的当前和未来方向。
Zotero 插件